CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 197 enrolled
Drug / intervention
AO-128drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02287402
NCT02287402Phase 4Completed
CompareCT.gov

Postmarketing Clinical Study on AO-128

Takeda·interventional·Posted Nov 10, 2014·Updated Apr 9, 2015

In Brief

A Phase 4 clinical trial evaluating AO-128 for Impaired Glucose Tolerance (IGT). Completed, enrolled 197 participants.

Detailed Summary

The purpose of open-label study is to evaluate the efficacy and safety of AO-128 (Voglibose) 0.6 mg/day in patients with impaired glucose tolerance (IGT) who had been non-responsive to diet therapy and exercise therapy, and follow up the progress after the end of treatment in patients who was assessed as normoglycemic.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImpaired Glucose Tolerance (IGT)
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 10, 2014
Enrollment StartMar 1, 2010
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.6 years ago

Interventions

AO-128drug

AO-128 tablet